Leishmania Tarentolae As a Platform for the Production of Vaccines Against Viral Pathogens

Overview

Journal NPJ Vaccines

Date 2024 Nov 6

PMID 39505865

Authors

Marta Zimna

Ewelina Krol

Affiliations

Soon will be listed here.

Abstract

Infectious diseases remain a persistent public health problem and a leading cause of morbidity and mortality in both humans and animals. The most effective method of combating viral infections is the widespread use of prophylactic vaccinations, which are administered to both people at risk of disease and animals that may serve as significant sources of infection. Therefore, it is crucial to develop technologies for the production of vaccines that are highly effective, easy to transport and store, and cost-effective. The protein expression system based on the protozoan Leishmania tarentolae offers several advantages, validated by numerous studies, making it a good platform for producing vaccine antigens. This review provides a comprehensive overview into the potential applications of L. tarentolae for the safe production of effective viral antigens.

References

Shirbaghaee Z, Bolhassani A, Mirshafiey A, Motevalli F, Zohrei N . A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo. Iran J Cancer Prev. 2016; 8(6):e3991. PMC: 4736072. DOI: 10.17795/ijcp-3991. View

Breitling R, Klingner S, Callewaert N, Pietrucha R, Geyer A, Ehrlich G . Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expr Purif. 2002; 25(2):209-18. DOI: 10.1016/s1046-5928(02)00001-3. View

Panasiuk M, Zimmer K, Czarnota A, Narajczyk M, Peszynska-Sularz G, Chraniuk M . Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy. J Nanobiotechnology. 2022; 20(1):160. PMC: 8961490. DOI: 10.1186/s12951-022-01357-1. View

Jones J, Sullivan P, Curran J . Progress in the HIV epidemic: Identifying goals and measuring success. PLoS Med. 2019; 16(1):e1002729. PMC: 6338352. DOI: 10.1371/journal.pmed.1002729. View

Beddoe A . Elimination of cervical cancer: challenges for developing countries. Ecancermedicalscience. 2020; 13:975. PMC: 6946419. DOI: 10.3332/ecancer.2019.975. View

Salat J, Formanova P, Hunady M, Eyer L, Palus M, Ruzek D . Development and testing of a new tick-borne encephalitis virus vaccine candidate for veterinary use. Vaccine. 2018; 36(48):7257-7261. DOI: 10.1016/j.vaccine.2018.10.034. View

Fischer K, Pinho Dos Reis V, Finke S, Sauerhering L, Stroh E, Karger A . Expression, characterisation and antigenicity of a truncated Hendra virus attachment protein expressed in the protozoan host Leishmania tarentolae. J Virol Methods. 2015; 228:48-54. DOI: 10.1016/j.jviromet.2015.11.006. View

Rodriguez F, John S, Iniguez E, Montalvo S, Michael K, White L . and Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors. Antimicrob Agents Chemother. 2020; 64(6). PMC: 7269496. DOI: 10.1128/AAC.01422-19. View

Nii-Trebi N . Emerging and Neglected Infectious Diseases: Insights, Advances, and Challenges. Biomed Res Int. 2017; 2017:5245021. PMC: 5327784. DOI: 10.1155/2017/5245021. View

10.

Dumpa N, Goel K, Guo Y, McFall H, Pillai A, Shukla A . Stability of Vaccines. AAPS PharmSciTech. 2019; 20(2):42. DOI: 10.1208/s12249-018-1254-2. View

11.

Jones K, Patel N, Levy M, Storeygard A, Balk D, Gittleman J . Global trends in emerging infectious diseases. Nature. 2008; 451(7181):990-3. PMC: 5960580. DOI: 10.1038/nature06536. View

12.

Lehrer A, Holbrook M . Tick-borne Encephalitis Vaccines. J Bioterror Biodef. 2013; 2011(Suppl 1):3. PMC: 3755374. DOI: 10.4172/2157-2526.S1-003. View

13.

Whitehorn J, Yacoub S . Global warming and arboviral infections. Clin Med (Lond). 2019; 19(2):149-152. PMC: 6454362. DOI: 10.7861/clinmedicine.19-2-149. View

14.

Flahault A, Vergu E, Coudeville L, Grais R . Strategies for containing a global influenza pandemic. Vaccine. 2006; 24(44-46):6751-5. DOI: 10.1016/j.vaccine.2006.05.079. View

15.

Wiese M, Ilg T, Lottspeich F, Overath P . Ser/Thr-rich repetitive motifs as targets for phosphoglycan modifications in Leishmania mexicana secreted acid phosphatase. EMBO J. 1995; 14(6):1067-74. PMC: 398183. DOI: 10.1002/j.1460-2075.1995.tb07089.x. View

16.

Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009; 5(10):705-19. DOI: 10.4161/hv.5.10.9518. View

17.

Castillo-Leon J, Trebbien R, Castillo J, Svendsen W . Commercially available rapid diagnostic tests for the detection of high priority pathogens: status and challenges. Analyst. 2021; 146(12):3750-3776. DOI: 10.1039/d0an02286a. View

18.

MacLennan C . Vaccines for low-income countries. Semin Immunol. 2013; 25(2):114-23. DOI: 10.1016/j.smim.2013.05.004. View

19.

Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N . VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1. Protein Expr Purif. 2015; 116:7-11. DOI: 10.1016/j.pep.2015.08.024. View

20.

Sanchez-Garcia L, Martin L, Mangues R, Ferrer-Miralles N, Vazquez E, Villaverde A . Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Fact. 2016; 15:33. PMC: 4748523. DOI: 10.1186/s12934-016-0437-3. View